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Abstract
Background: Atrial fibrillation is common in patients with structural heart disease who are undergoing cardiac
surgery. Surgical CryoMaze has been shown to be an effective treatment in several trials, but success rates
have varied considerably, between 47–95 %. The sequential hybrid approach, combining surgical CryoMaze
followed by radiofrequency catheter ablation, can achieve high freedom from atrial arrhythmias, even when
rigorous methods to detect arrhythmias after the procedure are used. However, data from randomized trials
comparing hybrid ablations to surgical ablations alone are lacking.
Methods/Design: The SurHyb study is a prospective, multicenter, randomized study. Patients with persistent or
long-standing persistent atrial fibrillation will be randomized to either surgical CryoMaze alone or surgical CryoMaze
followed by catheter ablation 3 months post-surgery. The primary outcome measure is arrhythmia-free survival without
class I or III antiarrhythmic drugs, which will be evaluated using 7-day ECG Holter monitoring at 24 months. A total of
260 patients will be investigated from three medical centers in the Czech Republic to obtain the relevant information.
Discussion: This is the first randomized study that compares surgical CryoMaze alone with the staged hybrid surgical
CryoMaze followed by catheter ablation in patients with persistent or long-standing persistent atrial fibrillation. These
results will contribute to the optimization of the treatment for these patients.
Trial registration: Czech Clinical Trials Registry, cz-301020151253. Registered on 30 October 2015.
Keywords: Atrial fibrillation, Catheter ablation, Surgical ablation, CryoMaze, Randomized controlled clinical trial, Hybrid
approach
Abbreviations: AF, Atrial fibrillation; E/A ratio, Early to late diastolic filling ratio; ECG, Electrocardiographic; PRHACA
Prospective, Randomized Comparison of Hybrid Ablation vs. Catheter Ablation
Background
Atrial fibrillation (AF), the most common clinically sig-
nificant cardiac arrhythmia, is associated with increased
mortality and morbidity [1]. The incidence of AF will
continue to increase due to aging of the population. In
patients indicated for cardiac surgery, the prevalence of
AF is higher compared to the general population [2],
and it can be as high as 50 % in individuals with mitral
valve disease [3].
Both surgical and catheter ablation have become
recognized treatments for symptomatic and drug-refractory
AF. The CryoMaze ablation procedure was developed
as a surgical alternative to cut-and-sew procedures as
a way to decrease invasiveness [4]. A variety of surgical
ablation energy sources have been used including micro-
waves, laser, and unipolar or bipolar radiofrequency
energy. The CryoMaze operation is usually done in
conjunction with a coronary bypass operation, valve
surgery, or other open heart surgery. Incomplete lines
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after surgical ablation are common and can be pro-
arrhythmic [5, 6]. The efficacy of the CryoMaze
procedure as the sole treatment for persistent AF has
been shown in several studies, but the results are
hindered by small patient numbers and less than accurate
follow-up assessments of heart rhythm, such as via
telephone interviews with only occasional use of conti-
nuous electrocardiographic (ECG) recordings [4, 7]. This
has led to mixed results, with rates of freedom from AF
being reported between 47–95 % [8, 9]. Additionally, the
need for subsequent transvenous catheter procedures
remains unknown; also, the clinical procedures employed
varied between centers.
In a non-randomized study, sequential surgical Cryo-
Maze procedures followed by catheter ablation led to
high freedom from arrhythmia in patients with persis-
tent and long-standing persistent AF and without an
increase in complications [10]. However, there have been
no randomized clinical trials conducted to evaluate
whether the hybrid approach is superior to a CryoMaze
procedure alone; therefore, a recommendation regarding
the best procedure for all patients is unavailable.
The aim of this randomized, multicenter clinical trial
is to compare clinical efficacy and safety of the staged
hybrid ablation to a CryoMaze procedure alone in a
well-described population of patients with AF.
Methods
The Sequential Hybrid Surgical CryoMaze Ablation versus
Surgical CryoMaze Alone for the Treatment of Atrial
Fibrillation (SurHyb) study was designed to be a prospec-
tive, randomized multicenter study. Patients will be
recruited from three major cardiovascular centers in the
Czech Republic (South Bohemia Cardiac Centre in
Budweis, the Institute for Clinical and Experimental
Medicine in Prague, and Na Homolce Hospital in Prague).
Patients will be approached during the clinical review
before the surgical operation and will be offered an
opportunity to participate in the study. There will be a fol-
low-up period of 2 years for each enrolled patient.
The objective of the study is to compare a staged hybrid
surgical cryoablation, followed 3 months later by catheter
ablation, to a surgical CryoMaze alone. A flowchart of
the SurHyb trial is shown in Fig. 1. Written informed
consent will be obtained from all patients prior to the
study. All participating centers will have an appointed
local investigator who will be responsible for appro-
priate inclusion and follow-up of patients. The trial
sponsor is the South Bohemia University in Budweis.
The regulations regarding medical confidentiality and
data protection are fulfilled.
Inclusion and exclusion criteria
All patients need to meet the following inclusion criteria:
1. Cardiac surgery (either valve operation or coronary
artery bypass grafting or combination of both) with
concomitant CryoMaze ablation as a treatment for
persistent or long-standing persistent AF
2. At least one failed class I or III antiarrhythmic drug
3. Age ≥18 years
4. Willing to sign the informed consent form
5. Symptomatic persistent or long-standing persistent
AF documented using electrocardiography;
Fig. 1 SurHyb study flowchart
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symptoms may include, but are not restricted to,
palpitations, shortness of breath, chest pain, fatigue,
left ventricular dysfunction, or any combination
of these
6. Able and willing to comply with all pre-, post-,
and follow-up testing and requirements
The exclusion criteria are as follows:
1. Permanent and paroxysmal AF
2. Previous surgical or catheter ablation for AF
(does not include ablation for atrial flutter or
other supraventricular arrhythmia)
3. Clinically estimated life expectancy of 5 years or less
or mental and/or physical inability to comply with
the follow-up period
4. Arrhythmia secondary to a reversible or non-cardiac
cause
5. Serious liver or renal dysfunction
(alanine aminotransferase [ALT] >80 U/l,
aspartate aminotransferase [AST] >80 U/l,
creatinine >132 μmol/l)
6. Pregnancy or the possibility of pregnancy,
or breast feeding
7. Age younger than 18 years
8. Contraindication to systemic anticoagulation
9. Enrollment in an experimental study evaluating
another device or drug under investigation
10.Patient not competent to legally represent him
or herself (e.g., requires a guardian or caretaker
as a legal representative)
Screening and enrollment
Approximately 600 patients per year are scheduled for
cardiac surgery with concomitant CryoMaze ablation in
all three cardiovascular centers involved in the study.
The patients who fulfill the inclusion criteria will be
approached by the local investigator, who will explain
the SurHyb study and provide a patient information
form. We expect that 50–70 % of eligible patients will
consent.
Randomization
The SurHyb study is a prospective, randomized, multi-
center study. After providing informed consent, patients
will be randomly assigned using a computer system
to one of the two groups — the hybrid group or the
surgery alone group — initially in a 1:1 ratio. The
surgeon will be blinded as to the treatment group
until the surgery is completed. All patient data will
be collected using a standard form and transmitted to
a central database.
Interventions
The study consists of two study arms: the hybrid group,
which will receive surgical CryoMaze followed, in
3 months, by catheter ablation in all patients, or the
surgical CryoMaze group, in which participants will
receive surgical cryoablation with no planned catheter
ablation after discharge.
Primary outcome measure
The primary outcome measure is arrhythmia-free
survival without class I or III antiarrhythmic drugs,
which will be evaluated using a 7-day Holter monitoring
at 24 months. After a 3-month blanking period, if a
patient requires a repeat ablation, cardioversion, or anti-
arrhythmic drugs, this will be considered as a failure.
Secondary outcome measures
The secondary outcome measures involve arrhythmia-
free survival without class I or III antiarrhythmic drugs
and without a need for repeat ablation or cardioversion,
evaluated using a 7-day Holter monitoring at 6, 12, and
18 months. The measures include:
 Arrhythmia-free survival regardless of
antiarrhythmic drugs status or re-do ablations
 Number of cardioversions
 Number of re-do ablations
 Frequency and duration of hospital admissions for
recurrent arrhythmias
 Frequency and description of any procedure-related
complications (during both surgical and catheter
ablation)
 Cardiovascular mortality and morbidity
 Changes of left atrial dimension as measured using
ultrasound echocardiography
Anticoagulation therapy before ablation
Patients on warfarin, apixaban, dabigatran, or rivaro-
xaban will stop the medication and switch to either
unfractionated or low molecular weight heparin, which
will be maintained during the surgical procedure. Novel
oral anticoagulants can only be used in accordance with
current recommendations during the trial [11]. If the
patient is taking only aspirin, it may or may not need to
be discontinued.
Surgical ablation
The CryoMaze ablation will be performed as an adjunct
to a coronary artery bypass, valve surgery, or a combi-
nation of both. It will be done using the standard
sternotomy approach, and each lesion will be created by
an application of cryothermia at a fixed temperature.
The target temperature, duration of application, and
location of each lesion will be recorded. The standard
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minimum CryoMaze protocol will consist of continuous
lesions surrounding each group of right and left pul-
monary veins with linear lesions between the superior
and inferior pulmonary veins with the aim of creating a
box lesion. Other lines can be created at the surgeon’s
discretion. The left atrial appendage will be excluded
in patients with a previous history of stroke or a
CHA2DS2-VASc score ≥2. All patients who remain in
AF after the surgical procedure is completed will
undergo attempted cardioversion before chest closure
and again before hospital discharge if the arrhythmia
persists. Patients will be left on their current antiar-
rhythmic medication covering the 3-month blanking
period to avoid early recurrences, with the aim of
discontinuing the medication at the first follow-up
visit. Recurrences of AF, atrial tachycardias, or atrial
flutter during the first 3 months may require a change of
the antiarrhythmic medication or direct current cardiover-
sion, but this will not be counted against the primary or
secondary endpoints. The patients will continue with the
same anticoagulation therapy after the operation unless a
change in the medication has been required during the
admission (e.g., anticoagulation for a newly implanted
artificial valve or discontinuation of anticoagulation for
severe bleeding). A 7-day ECG Holter monitor will be
scheduled 3 months after surgery (just before admission
for the catheter ablation in the hybrid group). If a patient
in the surgical cryoablation group is in persistent AF after
the 3-month blanking period, the patient will receive
direct current cardioversion, and if he or she remains in
normal sinus rhythm, this will not be considered a failure.
Catheter ablation
Patients randomized to the hybrid treatment arm will be
admitted for a staged catheter ablation treatment
3 months after the CryoMaze procedure. In general,
patients will continue with warfarin or stop one of the
novel anticoagulation drugs 24–48 hours before the
planned procedure (unless the surgeon decides other-
wise). Electro-anatomical mapping of the left and right
atria will be performed using a CARTO navigation
system. First, an anatomical map will be created to provide
a first look at the actual locations of the CryoMaze
ablation lines (regions with voltage <0.1 mV). Pulmonary
vein isolation will be confirmed by the absence of signals
recorded using a multielectrode circular catheter. Com-
pleteness of all linear lesions created during the surgical
CryoMaze will be confirmed by a bidirectional conduction
block across the relevant line. Any gaps will be re-ablated
using radiofrequency catheter ablation. If the patient is in
atrial tachycardia at the beginning of the procedure, the
tachycardia will be mapped and ablated as the first step. If
the patient is in AF, an external electrical cardioversion
will be performed during the procedure to restore sinus
rhythm. The investigator can then add any of the current
ablation methods including substrate modification or
ablation of triggers induced by an isoproterenol infusion.
Inducibility of AF or atrial tachycardia at the end of the
procedure will be recorded. Patients will be discharged on
their current antiarrhythmic medication for the 3-month
blanking period with the aim of discontinuing the medica-
tion at the first follow-up visit. Any atrial tachyarrhyth-
mias that may occur during the blanking period after the
catheter ablation may require a change of the antiarrhyth-
mic medication or external cardioversion. Intravenous
heparin will be administered during the procedure, and
warfarin will continue post-operatively with a target inter-
national normalized ratio between 2.0 and 3.0. Alterna-
tively, novel oral anticoagulants, such as dabigatran,
apixaban, or rivaroxaban, will be prescribed for a period
of at least 3 months.
Follow-up
Clinical follow-up will be performed at 3, 6, 12, 18, and
24 months after the index procedure (surgical ablation
in the surgical cryoablation group and catheter ablation
in the hybrid group). Seven-day Holter monitoring will
be performed before each follow-up in all patients. The
absence or presence of atrial tachyarrhythmias on the
ECG Holter will be assessed, and any need for additional
ablation procedures, antiarrhythmic drugs, or cardiover-
sions after the blanking period will be considered as a
failure. Clinical status, medication, blood pressure, 12-lead
electrocardiogram, and any adverse events will be docu-
mented during every visit. Unless necessary, antiarrhyth-
mic drug therapy will be discontinued at the first follow-up
visit. Medical records will be reviewed at each visit to deter-
mine the moment of antiarrhythmic medication changes.
An echocardiogram will be performed within 1 week
following the surgical ablation or, if performed, within
1 week after the catheter ablation. Further echocardio-
grams will be performed at the 12 and 24 month follow-
ups. Left atrial size will be determined using the long-axis
parasternal view and the apical two-chamber view. In
addition, the left ventricular end systolic and the left
ventricular end diastolic diameter will be measured, and
diastolic function will be assessed by computing the ratio
of early to late diastolic filling, the E/A ratio.
Withdrawal of trial participants
Participants can withdraw from the trial at any time for
any reason without their medical care being affected.
Data already collected will continue to be used, and the
patients will be asked if they are still willing to provide
follow-up data. The reason for withdrawal will be docu-
mented whenever possible.
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Statistical methods
Absolute values of continuous variables will be expressed
using standard summary statistics, arithmetic mean,
standard deviation, and corresponding 95 % confidence
interval. The study is designed to compare recurrence
rates of AF or atrial tachycardia episodes at 24 months
between two treatment groups as the primary endpoint.
The arrhythmia-free survival rate is defined as the per-
centage of patients free of atrial arrhythmias. Fisher’s exact
test will be used for this categorical data to assess the
difference in frequency of arrhythmia recurrence. The
odds ratio and its 95 % confidence interval will be
estimated as a quantitative measure of risk in the asso-
ciation frequency table. Differences in continuous data
describing duration of arrhythmia recurrences will be
tested using Student’s t test. Kaplan-Meier curves will be
plotted to compare event-free survival time between both
groups. The log-rank test will be performed to compare
arrhythmia-free survival time distributions between the
study arms. Influence of mutually independent risk factors
will be quantified on the basis of the hazard ratio (HR)
and its 95 % confidence interval. Both univariate and
multivariate adjusted HRs will be estimated using the Cox
proportional hazard models with an adopted forward
stepwise algorithm. All variables will be analyzed on the
basis of the intention-to-treat protocol. A P value less than
0.05 will be considered as a boundary of statistical signi-
ficance of differences in all performed tests. Analyses
will be performed using SPSS version 16.0 (SPSS Inc.,
Chicago, IL, USA).
Sample size calculation
Power calculations to provide estimates for the necessary
sample size were conducted concerning recurrence rates
of AF or atrial tachycardia episodes at 24 months as the
primary outcome endpoint. The clinical efficacy of the
hybrid ablation procedure was assumed to be 86 %,
whereas the efficacy of the surgical ablation alone was
assumed to be 50–70 %. To ensure 80 % power of the
Fisher exact test at the 5 % significance level, a sample
size of at least 130 must be included in each of the trial
arms. Considering a dropout rate of 20 %, approximately
170 patients will finally be recruited for each trial arm.
At the end of the study, the number of patients free
from arrhythmias should be similar in both groups, but
the proportion of those submitted to another procedure,
commenced on antiarrhythmic drugs, or undergoing
cardioversion should differ significantly.
Data management
A tailor-made website has been developed for the
SurHyb study. Each participating medical center will have
access to a dedicated part of the website. After enrollment
and randomization of participants, data from medical
records, drug regimens, interviews, and electrocardio-
grams will be added to the website. The website will be
updated after each outpatient clinical visit during the
follow-up period. The follow-up status of all patients can
be viewed instantly.
At the end of the study, all data will be entered
and stored on a password-protected computer. A data
monitoring committee, of which at least two members will
be independent of the research team, will monitor the
data management process regularly. All data will be frozen
and locked to prevent further editing after validation by
the data monitoring committee. Only the data monitoring
committee, the study research assistant, and the principal
investigator will have access to the final data set. This
committee will meet twice per year. Using statistical
criteria for acceptable deviations from the null hypothesis,
the committee will advise whether the recruitment can
continue or whether the study should be terminated. The
final analysis will be performed after all the patients
complete their 2-year follow-up.
Reasons for dropouts and the number of patients in
each group will be reported. This information will be
used to see how missing data will be handled in statis-
tical analysis. Data already collected will continue to be
used and, if possible, post-dropout data will be collected
on the main endpoints. In case of a high percentage of
missing data, imputation techniques might be required.
Safety monitoring
The local investigator at each site will review safety data
for the duration of the trial. Serious adverse events are
defined as life-threatening events or events resulting in
death or hospitalization. All serious adverse events
linked with the study will be reported to the Budweis
Hospital research ethics committee within 24 hours of
study staff becoming aware of the event and in accor-
dance with the institutional research ethics committee
requirements. Serious adverse events will be completed
with detailed information, such as event description,
date of onset and resolution, severity, and action taken.
Discussion
This randomized controlled trial is the first of its kind in
which hybrid ablation will be compared with surgical
CryoMaze alone to compare differences relative to free-
dom from atrial tachyarrhythmia.
CryoMaze ablation is a less invasive modification of
the original cut-and-sew method using a cryoprobe to
create ablation lesions. Success rates have been reported
to be as high as 95 % at 12 months; however, follow-ups
were conducted through telephone interviews only [4].
When more accurate methods to determine heart
rhythm were used, such as ECG Holter monitors over
several days, success rates fell to 76 % at 12 months [9].
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Other authors have reported less promising outcomes.
In one study, only 47 % of patients with persistent AF who
underwent surgical CryoMaze with concomitant cardiac
surgery were in long-term normal sinus rhythm [8].
Hybrid ablations may overcome the limitations asso-
ciated with both surgical and transvenous endocardial
ablations alone. Neither of the approaches alone can
guarantee complete transmurality, which is crucial,
particularly with regard to persistent AF requiring rela-
tively long continuous lesions. It is also possible to ablate
arrhythmia triggers and inducible atrial tachycardias
after the surgical ablation; these would otherwise be left
untreated. Studies published to date included simulta-
neous or sequential hybrid procedures with reported
success rates from 83–94 %, but the experience has only
been with bipolar or monopolar radiofrequency energy
[12–15]. The only report on hybrid ablations with cryoe-
nergy used during the surgical part of the procedure
revealed an overall freedom from atrial tachyarrhythmias
to be 86 % at 12 months. The overall success rate at
1 year can reach 94 % if patients on antiarrhythmic
drugs or patients who underwent a successful re-do
ablation are not excluded as a failure [10]. There is
certainly reporting bias among published studies, as
several large studies of hybrid AF ablation, including the
staged Dual Epicardial Endocardial Persistent (DEEP) AF
study, FAST-II, and SCALA have not yet been published.
Data from randomized trials comparing hybrid abla-
tions to either surgical or catheter ablation are lacking,
but several randomized clinical trials are ongoing. The
staged transthoracic approach to persistent AF (TOP-
AF) study is a randomized controlled trial comparing
percutaneous catheter ablation with surgical ablation as
the first procedure followed by a second procedure, if
necessary [16]. The researchers anticipate that the use of
a staged strategy combining surgical and percutaneous
approaches might be more favorable in treatment of per-
sistent AF than a single percutaneous ablation. Another
ongoing trial (Prospective, Randomized Comparison of
Hybrid Ablation vs. Catheter Ablation, PRHACA) will
compare endocardial catheter ablation using the Arctic
Front CryoAblation catheter (Medtronic, Minneapolis,
MN, USA) to isolate the pulmonary veins and a
Navistar Smart Touch catheter (Biosense Webster,
Diamond Bar, CA, USA) to create ablation lines during
the hybrid surgical ablation using a VisiTrax ablation de-
vice (nContact, Morrisville, NC, USA) for the surgical por-
tion of the procedure. As far as we know, there are no
ongoing randomized trials using cryoenergy for the sur-
gical part of the hybrid procedure.
Trial status
The trial is currently in the recruitment phase.
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